Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation.
Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift
Standard
Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation. / Håkansson, Petra; Nilsson, Björn; Andersson, Anna; Lassen, Carin; Gullberg, Urban; Fioretos, Thoas.
I: Genes, Chromosomes and Cancer, Vol. 47, Nr. 4, 2008, s. 267-275.Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift
Harvard
APA
CBE
MLA
Vancouver
Author
RIS
TY - JOUR
T1 - Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation.
AU - Håkansson, Petra
AU - Nilsson, Björn
AU - Andersson, Anna
AU - Lassen, Carin
AU - Gullberg, Urban
AU - Fioretos, Thoas
N1 - (c) 2008 Wiley-Liss, Inc.
PY - 2008
Y1 - 2008
N2 - Philadelphia (Ph) chromosome-positive leukemia is characterized by the BCR/ABL1 fusion protein that affects a wide range of signal transduction pathways. The knowledge about its downstream target genes is, however, still quite limited. To identify novel BCR/ABL1-regulated genes we used global gene expression profiling of several Ph-positive and Ph-negative cell lines treated with imatinib. Following imatinib treatment, the Ph-positive cells showed decreased growth, viability, and reduced phosphorylation of BCR/ABL1 and STAT5. In total, 142 genes were identified as being dependent on BCR/ABL1-mediated signaling, mainly including genes involved in signal transduction, e.g. the JAK/STAT, MAPK, TGFB, and insulin signaling pathways, and in regulation of metabolism. Interestingly, BCR/ABL1 was found to activate several genes involved in negative feedback regulation (CISH, SOCS2, SOCS3, PIM1, DUSP6, and TNFAIP3), which may act to indirectly suppress the tumor promoting effects exerted by BCR/ABL1. In addition, several genes identified as deregulated upon BCR/ABL1 expression could be assigned to the TGFB and NFkB signaling pathways, as well as to reflect the metabolic adjustments needed for rapidly growing cells. Apart from providing important pathogenetic insights into BCR/ABL1-mediated leukemogenesis, the present study also provides a number of pathways/individual genes that may provide attractive targets for future development of targeted therapies. This article contains Supplementary Material available at http://www.interscience.wiley.com/jpages/1045-2257/suppmat.
AB - Philadelphia (Ph) chromosome-positive leukemia is characterized by the BCR/ABL1 fusion protein that affects a wide range of signal transduction pathways. The knowledge about its downstream target genes is, however, still quite limited. To identify novel BCR/ABL1-regulated genes we used global gene expression profiling of several Ph-positive and Ph-negative cell lines treated with imatinib. Following imatinib treatment, the Ph-positive cells showed decreased growth, viability, and reduced phosphorylation of BCR/ABL1 and STAT5. In total, 142 genes were identified as being dependent on BCR/ABL1-mediated signaling, mainly including genes involved in signal transduction, e.g. the JAK/STAT, MAPK, TGFB, and insulin signaling pathways, and in regulation of metabolism. Interestingly, BCR/ABL1 was found to activate several genes involved in negative feedback regulation (CISH, SOCS2, SOCS3, PIM1, DUSP6, and TNFAIP3), which may act to indirectly suppress the tumor promoting effects exerted by BCR/ABL1. In addition, several genes identified as deregulated upon BCR/ABL1 expression could be assigned to the TGFB and NFkB signaling pathways, as well as to reflect the metabolic adjustments needed for rapidly growing cells. Apart from providing important pathogenetic insights into BCR/ABL1-mediated leukemogenesis, the present study also provides a number of pathways/individual genes that may provide attractive targets for future development of targeted therapies. This article contains Supplementary Material available at http://www.interscience.wiley.com/jpages/1045-2257/suppmat.
KW - Benzamides
KW - Biomarkers, Tumor
KW - Blotting, Northern
KW - Blotting, Western
KW - Feedback, Physiological
KW - Fusion Proteins, bcr-abl
KW - Gene Expression Profiling
KW - Gene Expression Regulation, Leukemic
KW - Humans
KW - Imatinib Mesylate
KW - Leukemia, Myelogenous, Chronic, BCR-ABL Positive
KW - Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
KW - Oligonucleotide Array Sequence Analysis
KW - Philadelphia Chromosome
KW - Piperazines
KW - Protein Kinase Inhibitors
KW - Protein-Tyrosine Kinases
KW - Pyrimidines
KW - Signal Transduction
KW - Transcription, Genetic
KW - Tumor Cells, Cultured
KW - Journal Article
KW - Research Support, Non-U.S. Gov't
U2 - 10.1002/gcc.20528
DO - 10.1002/gcc.20528
M3 - Article
C2 - 18181176
VL - 47
SP - 267
EP - 275
JO - Genes, Chromosomes and Cancer
JF - Genes, Chromosomes and Cancer
SN - 1045-2257
IS - 4
ER -